Orchid Pharma shares hit 20% upper circuit as Investec initiates 'Buy' citing strong growth
Investec is bullish on Orchid Pharma's new management led by Dhanuka Group, as, according to the report, the management continues to execute the turnaround strategy well and leverages the company's core strengths in Cephalosporin Active Pharmaceutical Ingredients (APIs).
Orchid Pharma shares, Representative image. Source: Pexels